Tuberculosis Trials Consortium (TBTC)

FHI 360 is a member of the Tuberculosis Trials Consortium (TBTC), which conducts clinical, laboratory and epidemiologic research for the diagnosis, clinical management and prevention of TB infection and disease. The consortium’s goal is to find new and improved drugs and treatment strategies for treating and preventing TB among adults and children, either with or without HIV. Studies seek to shorten the treatment duration from six months to two months or less and to find shorter, less toxic treatment for latent TB infection. The consortium includes international and U.S.-based sites, including one in North Carolina managed by FHI 360 and Duke University. FHI 360 works in close collaboration with TB control programs across the state and with investigators and nurse study coordinators at Duke University Medical Center and at Carolinas Medical Center.